KIORA PHARMACEUTICALS INC
KPRX · NASDAQ
Updated at 2026-10-14 09:31:18
- Today's High
- $2.55
- Today’s Low
- $2.47
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $2.53
- Previous Close
- $2.56
- Volume
- 12.77K
- Market Cap
- $11.32M
- P/E Ratio
- --
- EPS
- $-2.47
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Pharmaceuticals
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 332 ENCINITAS BOULEVARD, ENCINITAS, CA, UNITED STATES, 92024
- Country
- US
- Listing Date
- 2015-02-13
- Fiscal Year End
- December
- Shares Outstanding
- 4.43M
- CIK
- 0001372514
- Website
- kiorapharma.com
Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology firm focused on developing innovative therapies for ocular diseases and neurodegenerative disorders. The company boasts a diverse pipeline of drug candidates aimed at addressing significant unmet medical needs, underpinned by its expertise in drug formulation and delivery. With a strong commitment to enhancing patient outcomes and a solid research framework, Kiora's strategic partnerships and clinical advancements underscore its potential within the biopharmaceutical sector, offering an attractive investment prospect for institutional investors looking to capitalize on the next generation of therapeutics.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$2.21M
2026-03-31
$2.46M
2025-12-31
$7.31M
2025-09-30
$794.43K
Net Income
2026-06-30
-$2.07M
2026-03-31
-$2.41M
2025-12-31
-$6.51M
2025-09-30
$26.8K
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-0.34
2026-03-31
$-0.58
2025-12-31
$-1.73
2025-09-30
$0.01
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$2.06M
2026-03-31
-$2.37M
2025-12-31
-$5.25M
2025-09-30
-$2.5M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
9.06%
2025-09-30
104.34%
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $2.21M | $2.46M | $7.31M | $794.43K |
| Net Income | -$2.07M | -$2.41M | -$6.51M | $26.8K |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-0.34 | $-0.58 | $-1.73 | $0.01 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$2.06M | -$2.37M | -$5.25M | -$2.5M |
| Effective Tax Rate | -- | -- | 9.06% | 104.34% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.